Zoetis today announced Lepto EQ Innovator®, the only equine leptospirosis vaccine against L. pomona, received additional approval for use in broodmares for all three trimesters of pregnancy. Field safety studies, which examined the vaccine when used in the first, second and third trimesters of pregnancy, showed no systemic or local reactions to vaccination.
“Leptospires can cause late-term abortion in mares,” said Jacquelin Boggs, DVM, MS, ACVIM, senior veterinarian, Equine Technical Services at Zoetis. “The expanded label claim allows the equine breeding community the flexibility to use Lepto EQ Innovator® to fit their breeding program's needs and help elevate antibody titer levels when most needed.”
A study showed that 13 percent of bacterial abortions are caused by L. pomona, the most common leptospiral serovar found in horses. Aborting mares have been reported to shed leptospires in their urine for periods up to three months and can transmit Leptospira to exposed animals. Some horses aborting due to leptospiral infection develop uveitis several weeks to months later. Additionally, the aborted fetus is a source of exposure to other horses on the property.
Prior to launching Lepto EQ Innovator®, Zoetis conducted intensive safety and efficacy trials which showed 0 percent urinary shedding in vaccinated horses challenged with L. pomona. Additional studies showed 99.8 percent of vaccinated horses were reaction-free with no adverse events.
“The additional field safety study in first and third trimester mares was conducted following the launch of Lepto EQ Innovator® to provide veterinarians and horse owners confidence in the vaccine across all phases of pregnancy,” said Dr. Boggs. “Additionally, the study highlights the ongoing dedication from Zoetis to provide the equine industry a product they can have confidence in.”
New to the Paulick Report? Click here to sign up for our daily email newsletter to keep up on this and other stories happening in the Thoroughbred industry.
Copyright © 2020 Paulick Report.